Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median du...

Descripción completa

Detalles Bibliográficos
Autores principales: Maerevoet, Marie, Zijlstra, Josee M., Follows, George, Casasnovas, Rene-Olivier, Vermaat, J. S. P., Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Van Den Neste, Eric, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Canales, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283921/
https://www.ncbi.nlm.nih.gov/pubmed/34271963
http://dx.doi.org/10.1186/s13045-021-01122-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283921/
https://www.ncbi.nlm.nih.gov/pubmed/34271963
http://dx.doi.org/10.1186/s13045-021-01122-1

Ejemplares similares